Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases — Stella

Home/Relapsing or Refractory Multiple Sclerosis (MS)/CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

View on ClinicalTrials.gov

Recruiting

Back to Relapsing or Refractory Multiple Sclerosis (MS) trials

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Key details

Phase

Very early testing

Sponsor

Daishi Tian

Collaborators

Nanjing Bioheng Biotech Co., Ltd.

Enrollment target

~36 participants

Started

December 2025

Primary completion

December 2026

Age range

18 Years – 70 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.